Team:uOttawa/policy

From 2014.igem.org

(Difference between revisions)
Line 160: Line 160:
                 <p>Furthermore, one of the most promising ideas raised at the conference was to link iGEM teams with industry. After all, iGEM teams are trying to solve real-world problems using synthetic biology and industries have the knowledge of what problems exist and need to be solved. It was discussed that Dennis, the coordinator of oGEM, will work on establishing contacts with industries and will subsequently match these industries with iGEM teams at a conference that would take take place in January of 2015. This conference would allow both industries and iGEM teams to communicate what it is that they can provide in this partnership. This would give the iGEM teams several months to develop their ideas and would allow Policy teams to brainstorm ideas for projects related to the wet lab, since the wet lab project would be already known by the beginning of summer.</p>
                 <p>Furthermore, one of the most promising ideas raised at the conference was to link iGEM teams with industry. After all, iGEM teams are trying to solve real-world problems using synthetic biology and industries have the knowledge of what problems exist and need to be solved. It was discussed that Dennis, the coordinator of oGEM, will work on establishing contacts with industries and will subsequently match these industries with iGEM teams at a conference that would take take place in January of 2015. This conference would allow both industries and iGEM teams to communicate what it is that they can provide in this partnership. This would give the iGEM teams several months to develop their ideas and would allow Policy teams to brainstorm ideas for projects related to the wet lab, since the wet lab project would be already known by the beginning of summer.</p>
                 <p>In addition to serving as a liaison between industry and individual iGEM teams, Dennis will also be able to provide assistance to iGEM teams by connecting them to services they might require such as an up-to-date database of bacterial strains that can be viewed by all iGEM teams. In an effort to establish and maintain a strategic and long-term industry partnership, each team will assign an oGEM Delegate who will be the contact point for Dennis to communicate the interests of industries to their partnered iGEM teams. To continue the collaborative effort to further expand iGEM, an advisory board will be formed which will allow PIs interested in teaching and research to coordinate long-term collaborations with industries and create a nurturing environment for synthetic biology to thrive and flourish.</p>
                 <p>In addition to serving as a liaison between industry and individual iGEM teams, Dennis will also be able to provide assistance to iGEM teams by connecting them to services they might require such as an up-to-date database of bacterial strains that can be viewed by all iGEM teams. In an effort to establish and maintain a strategic and long-term industry partnership, each team will assign an oGEM Delegate who will be the contact point for Dennis to communicate the interests of industries to their partnered iGEM teams. To continue the collaborative effort to further expand iGEM, an advisory board will be formed which will allow PIs interested in teaching and research to coordinate long-term collaborations with industries and create a nurturing environment for synthetic biology to thrive and flourish.</p>
 +
            </div>
 +
<div class="pane" id="pane-law" hidden>
 +
                <h1>Genetics and Patent Law</h1>
 +
                <p>A question came out of our wet lab this year that served as a springboard for related questions and speculations regarding ease of sharing in the realm of synthetic biology research. This initial question was the following: "Our lab received a part from a colleague in the United States. Although no patent exists for this part, the US lab offered it exclusively to our research team (as per email correspondence). Could our team submit this genetic sequence to the Registry of Standard Parts, which would make it available to all iGEM teams?"" Although the vast majority of our team members were immediately inclined to answer no, with the question seemingly being one of courtesy if nothing more, it got us thinking nonetheless. If the sequence were indeed patented, how would our presence in Canada (as opposed to the US) influence how we might be able to use and share this sequence? And how do we foster collaboration between American and Canadian scientists, and even better, how do we foster international collaboration? </p>
 +
                <p>The following infographic outlines what we have set out to do:</p>
 +
                <figure>
 +
                    <a target="_blank" href="https://static.igem.org/mediawiki/2014/f/f0/Uo2014-pat1.png"><img src="https://static.igem.org/mediawiki/2014/f/f0/Uo2014-pat1.png" alt=""></a>
 +
                    <p>Click to enlarge</p>
 +
                </figure>
 +
                <p>Our team has arranged to meet with a few experts on law and policy to discuss our thoughts and questions. We also wanted to get an idea of what students in science and/or law thought about these questions, so we designed a survey to do just that. The survey asked 6 main questions, not including questions about students' background.</p>
 +
                <ol>
 +
                    <li>Should genetic sequences be patentable?</li>
 +
                    <li>If a patent exists for a particular genetic sequence, where should the patent be applicable?</li>
 +
                    <li>If a patent on a genetic sequence hinders the advancement of science or stands in the way of the public good, should the patent be restricted or terminated?</li>
 +
                    <li>Who should decide when a patent is hindering scientific advancement?</li>
 +
                    <li>How do we encourage collaboration between American and Canadian synthetic biologists? </li>
 +
                    <p>And the question that started it all: </p>
 +
                    <li>Our lab received a part from a colleague in the United States. Although no patent exists for this part, the US lab offered it exclusively to our research team (as per email correspondence). Could our team submit this genetic sequence to the Registry of Standard Parts, which would make it available to all iGEM teams (internationally)?</li>
 +
                </ol>
 +
                <p>The two infographics below present the results of this survey:</p>
 +
                <figure class="half">
 +
                    <a target="_blank" href="https://static.igem.org/mediawiki/2014/c/c0/Uo2014-pat2.jpg"><img src="https://static.igem.org/mediawiki/2014/c/c0/Uo2014-pat2.jpg" alt=""></a>
 +
                    <p>Click to enlarge</p>
 +
                </figure>
 +
                <figure class="half">
 +
                    <a target="_blank" href="https://static.igem.org/mediawiki/2014/7/77/Uo2014-pat3.jpg"><img src="https://static.igem.org/mediawiki/2014/7/77/Uo2014-pat3.jpg" alt=""></a>
 +
                    <p>Click to enlarge</p>
 +
                </figure>
 +
                <h2>Conclusions</h2>
 +
                <p>In answering whether or not genetic sequences should be patentable, a large portion of respondents assumed the discussion involved naturally occurring genetic sequences and thus identified that option as unacceptable. However, interestingly enough, most respondents agreed that should a patent exist, it should be applicable everywhere around the world. This perhaps suggests a perceived significance of intellectual property. Also appearing of very high significance to student respondents are scientific advancement and the general good. All but one of those surveyed agreed that a patent should be restricted if either scientific advancement or the public good is affected. Among the suggestions for encouraging collaboration between synthetic biologists, one recurring idea called for an open-access database of genetic sequences. Here, we cannot help but think of the Registry of Standard Parts and the role that it is playing in performing this exact function internationally. Finally, 17 out of 23 respondents agreed that our lab should not submit the sequence we received from a US colleague (refer to paragraph one on this page), at least not without permission of the lab who sent it to us. This aligns with our team’s perceptions as well, as discussed earlier</p>
             </div>
             </div>
         </div>
         </div>

Revision as of 14:54, 17 October 2014

Let's Talk Science

In an effort to extend our reach into our university and city communities, the University of Ottawa iGEM Human Practices Team partnered up with Let's Talk Science for the 2014 season. Let's Talk Science is an award-winning, national organization that creates and delivers programs to engage youth and educators in science, technology, engineering and math (STEM). As a team, we recognized that our interests as Policy and Practices overlapped with the interests of Let's Talk Science in educating youth about the possibilities that science, including the field of synthetic biology, brings. We established communication with the Ottawa Chapter of Let's Talk Science and a great partnership was established for the 2014 season.

Through our collaboration with LTS, we were able to set up an iGEM station at the Let’s Talk Science Challenge, an annual event that brings together a large group of students from Grades 6, 7 and 8. These students participate in a science trivia competition for the first half of the day and face-off in a design challenge later in the day. By setting up a station at this event in Ottawa, we were able to reach tens of elementary-aged students and introduce them to the concepts of synthetic biology in a fun and engaging manner (see below). In return, our iGEM Team members volunteered their time to help score both the trivia competition and the design challenge.

Our booth at the Let's Talk Science challenge, featuring Mr. Cool's Microscopic Adventures books (uOttawa iGEM Human Practices 2013), a Think Challenge that asked participating young students to think of the craziest idea synthetic biology could help us achieve and a bracelet-making activity that was based on a 'DNA code' where different colour beads represented the base pairs in amino acid codons.

Furthermore, in the context of this partnership, a few members of our Human Practices Team were able to participate in a training workshop offered by Let's Talk Science to improve their skills as youth science educators. This served to enhance our ability to communicate science concepts to the general public, specifically to a young audience.

As an established organization in the Ottawa community, Let's Talk Science had prior contact with elementary, middle and high schools across the city. They were able to advertise our offer of synthetic biology-oriented presentations to these schools and the response was huge and immediate.